Understand the source comparison
Dihexa Side Effects Long Term Research: Comparison Across Cognitive Peptides
Dihexa HGF/c-Met agonist No trials beyond anecdotal 12-week use Unknown. No multi-year human data exists Not FDA-approved; research-grade only Promising preclinical profile undermined by complete absence of Phase II/III safety trials Semax ACTH(4-10) analogue
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dihexa
- HGF/c-Met agonist
- No trials beyond anecdotal 12-week use
- Unknown. No multi-year human data exists
- Not FDA-approved; research-grade only
- Promising preclinical profile undermined by complete absence of Phase II/III safety trials
- Semax
- ACTH(4-10) analogue with BDNF modulation
- Russian clinical use spanning decades; limited Western trials
- Well-tolerated in clinical settings; no cancer or cardiovascular signals in long-term Russian literature
- Approved in Russia; unapproved elsewhere
- Established safety record in specific populations but limited independent replication
- Cerebrolysin
- Porcine brain-derived peptide mixture
- Trials up to 28 weeks in stroke recovery
- Rare allergic reactions; immune response to animal-derived peptides possible
- Approved in multiple countries for stroke/TBI
- Decades of clinical use provide reassurance; immunogenicity remains theoretical concern
- P21 (Cerebrolysin-derived fragment)
- CNTF pathway activation
- No human trials; rodent studies only
- Unknown. Even less human data than dihexa
- Research-only; no clinical approval
- Mechanistically distinct from dihexa but suffers identical long-term safety gap
- Dihexa's regulatory stasis reflects funding realities more than safety signals. ASU holds the original patents, but no pharmaceutical partner has advanced it through FDA Investigational New Drug (IND) pathways. Without Phase I dose-ranging trials establishing maximum tolerated dose in healthy humans, Phase II efficacy studies in target populations (Alzheimer's, TBI) can't proceed. The compound remains legally available as a research chemical under the assumption purchasers are qualified investigators conducting institutional-review-board-approved studies. An assumption violated daily.
- The most structurally similar comparator is Cerebrolysin, which has multi-decade clinical use in stroke recovery and neurodegenerative conditions. While cerebrolysin's peptide mixture acts through different pathways (neurotrophic factor delivery rather than receptor modulation), its established safety profile demonstrates that peptide-based cognitive interventions can achieve regulatory approval and post-market surveillance when developed through standard pharmaceutical pipelines. Dihexa hasn't followed that path.